Welcker K, Schneider M, Reese T, Ehrenfeld A, Weilert H, Stang A
PLoS One. 2025; 20(3):e0307937.
PMID: 40053536
PMC: 11888131.
DOI: 10.1371/journal.pone.0307937.
Prajapati J, Bhatt N, Rawal R
Arch Toxicol. 2024; 99(3):887-914.
PMID: 39729113
DOI: 10.1007/s00204-024-03928-7.
Wang Y, Mao S, Huang R, Li S, Luo R, Shen J
Eur Radiol. 2024; .
PMID: 39532721
DOI: 10.1007/s00330-024-11185-6.
Gupta N, Verma N, Patel B
J Gastrointest Cancer. 2024; 55(4):1485-1497.
PMID: 39160369
DOI: 10.1007/s12029-024-01103-w.
Song Q, Zheng Y, Zhong G, Wang S, He C, Li M
Anticancer Agents Med Chem. 2024; 24(18):1305-1326.
PMID: 39129164
PMC: 11497148.
DOI: 10.2174/0118715206323900240807110122.
Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations.
Kim J, Randhawa H, Sands D, Lambe S, Puglia M, Serrano P
Bladder Cancer. 2024; 7(3):261-278.
PMID: 38993608
PMC: 11181825.
DOI: 10.3233/BLC-211536.
Chemotherapy-associated liver morphological changes in hepatic metastases (CALMCHeM).
Pope M, Olson M, T Flicek K, Patel N, Bolan C, Menias C
Diagn Interv Radiol. 2023; 29(4):571-578.
PMID: 37310196
PMC: 10679643.
DOI: 10.4274/dir.2023.232299.
The Effect of Metformin on Chemotherapy-Induced Toxicities in Non-diabetic Breast Cancer Patients: A Randomised Controlled Study.
Serageldin M, Kassem A, El-Kerm Y, Helmy M, El-Mas M, El-Bassiouny N
Drug Saf. 2023; 46(6):587-599.
PMID: 37131014
PMC: 10220128.
DOI: 10.1007/s40264-023-01305-4.
Amelioration of cyclophosphamide-induced DNA damage, oxidative stress, and hepato- and neurotoxicity by extract in rats: The role of γH2AX and 8-OHdG.
Yadav V, Krishnan A, Zahiruddin S, Ahmad S, Vohora D
Front Pharmacol. 2023; 14:1147823.
PMID: 36969834
PMC: 10036401.
DOI: 10.3389/fphar.2023.1147823.
Concomitant Sub-Chronic Administration of Small-Size Gold Nanoparticles Aggravates Doxorubicin-Induced Liver Oxidative and Inflammatory Damage, Hyperlipidemia, and Hepatic Steatosis.
Alshammari G, Abdelhalim M, Al-Ayed M, Al-Harbi L, Yahya M
Molecules. 2023; 28(2).
PMID: 36677854
PMC: 9863023.
DOI: 10.3390/molecules28020796.
The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review.
George E, Sood S, Kiss N, Daly R, Nicoll A, Roberts S
Curr Oncol. 2023; 30(1):48-74.
PMID: 36661654
PMC: 9857873.
DOI: 10.3390/curroncol30010005.
Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response.
Minami Y, Aoki T, Chishina H, Takita M, Hagiwara S, Ida H
Cancers (Basel). 2022; 14(19).
PMID: 36230773
PMC: 9562238.
DOI: 10.3390/cancers14194850.
Evaluation of liver function tests to identify hepatotoxicity among acute lymphoblastic leukemia patients who are receiving chemotherapy induction.
Mekonnen A, Wondmeneh T
Sci Rep. 2022; 12(1):13215.
PMID: 35918381
PMC: 9346124.
DOI: 10.1038/s41598-022-17618-w.
Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis.
Calistri L, Rastrelli V, Nardi C, Maraghelli D, Vidali S, Pietragalla M
World J Gastroenterol. 2022; 27(46):7866-7893.
PMID: 35046618
PMC: 8678821.
DOI: 10.3748/wjg.v27.i46.7866.
Clinical implications of chemotherapeutic agent organ toxicity on perioperative care.
Zeien J, Qiu W, Triay M, Dhaibar H, Cruz-Topete D, Cornett E
Biomed Pharmacother. 2021; 146:112503.
PMID: 34922113
PMC: 11118057.
DOI: 10.1016/j.biopha.2021.112503.
Pseudocirrhosis after chemotherapy for gastric cancer with diffuse liver metastases: A case report.
Shinoda T, Tanahashi T, Sakuratani T, Ota M, Fujibayashi S, Kiriyama S
Mol Clin Oncol. 2021; 16(1):11.
PMID: 34881031
PMC: 8647196.
DOI: 10.3892/mco.2021.2441.
Imaging of chemotherapy-induced liver toxicity: an illustrated overview.
Torri G, Soldatelli M, Luersen G, Almeida Ghezzi C
Hepat Oncol. 2021; 8(4):HEP32.
PMID: 34765105
PMC: 8577512.
DOI: 10.2217/hep-2020-0026.
Animal models of chemotherapy-induced cognitive decline in preclinical drug development.
John J, Kinra M, Mudgal J, Viswanatha G, Nandakumar K
Psychopharmacology (Berl). 2021; 238(11):3025-3053.
PMID: 34643772
PMC: 8605973.
DOI: 10.1007/s00213-021-05977-7.
SAEgnal: A Predictive Assessment Framework for Optimizing Safety Profiles in Immuno-Oncology Combination Trials.
Prokop A, Zhang Y, Mukhopadhyay P, Khan F, Shameer K
AMIA Jt Summits Transl Sci Proc. 2021; 2021:535-544.
PMID: 34457169
PMC: 8378624.
Preclinical Toxicity and Safety of MM-129-First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer.
Hermanowicz J, Kalaska B, Pawlak K, Sieklucka B, Miklosz J, Mojzych M
Pharmaceutics. 2021; 13(8).
PMID: 34452183
PMC: 8400941.
DOI: 10.3390/pharmaceutics13081222.